# US 2006/0051745 A1 · HCV non-structural protein mutants and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0051745 A1
- Document ID: US20060051745A1
- Status: Published application
- Kind: A1
- Application number: 11/213,326
- Filed: 2005-08-26
- Published: 2006-03-09
- Earliest claimed: 2000-06-15
- Assignees: Chiron Corporation
- Inventors: David Chien; Doris Coit; Celine Hu; Sansan Lin; Angelica Medina-Selby
- Web page: https://patentgrep.com/patent/US20060051745A1

## CPC

- G01N 33/5767: {non-A, non-B hepatitis}
- C07K 14/005: from viruses
- C12N 2770/24222: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Modified HCV non-structural proteins are described. The proteins include modified NS3 domains such that proteolytic activity of the NS3 molecule is inhibited. The modified proteins retain conformational epitopes. HCV immunoassays including the modified NS3 molecules are also described.

## Claims

### Claim 1

An immunoassay solid support comprising a polypeptide comprising a modified hepatitis C virus (HCV) NS3 protease domain such that protease activity of the modified NS3 polypeptide is inhibited relative to protease activity of a corresponding HCV NS3 polypeptide lacking the modification, wherein said polypeptide comprises an NS3 conformational epitope and reacts specifically with anti-HCV antibodies present in a biological sample from an HCV-infected individual.

### Claim 2 (depends on 1)

The immunoassay solid support of claim 1, wherein the modification comprises a substitution of an amino acid corresponding to His-1083, Asp-1105 and/or Ser-1165, numbered relative to the full-length HCV-1 polyprotein.

### Claim 3 (depends on 2)

The immunoassay solid support of claim 2, wherein the modification comprises a substitution of Ala for the amino acid corresponding to Ser-1165, numbered relative to the full-length HCV-1 polyprotein.

### Claim 4 (depends on 1)

The immunoassay solid support of claim 1, wherein the polypeptide further comprises a substitution of Pro for the amino acid corresponding to Thr-1428 and a substitution of Ile for the amino acid corresponding to Ser-1429.

### Claim 5 (depends on 1)

The immunoassay solid support of claim 1, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:2.

### Claim 6 (depends on 5)

The immunoassay solid support of claim 5, wherein the polypeptide consists of the amino acid sequence of SEQ ID NO:2.

### Claim 7 (depends on 1)

The immunoassay solid support of claim 1, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:4.

### Claim 8 (depends on 7)

The immunoassay solid support of claim 7, wherein the polypeptide consists of the amino acid sequence of SEQ ID NO:4.

### Claim 9 (depends on 1)

The immunoassay solid support of claim 1, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:6.

### Claim 10 (depends on 9)

The immunoassay solid support of claim 9, wherein the polypeptide consists of the amino acid sequence of SEQ ID NO:6.

### Claim 11 (depends on 1)

The immunoassay solid support of claim 1, wherein the solid support further comprises a multiple epitope fusion antigen bound to the support, wherein said polypeptide and/or said multiple epitope fusion antigen react specifically with anti-HCV antibodies present in a biological sample from an HCV-infected individual.

### Claim 12 (depends on 11)

The immunoassay solid support of claim 11, wherein said multiple epitope fusion antigen comprises the amino acid sequence depicted in SEQ ID NO:10, or an amino acid sequence with at least 80% sequence identity thereto which reacts specifically with anti-HCV antibodies present in a biological sample from an HCV-infected individual.

### Claim 13 (depends on 11)

The immunoassay solid support of claim 11, wherein said multiple epitope fusion antigen comprises the amino acid sequence depicted in SEQ ID NO:10, or an amino acid sequence with at least 90% sequence identity thereto which reacts specifically with anti-HCV antibodies present in a biological sample from an HCV-infected individual.

### Claim 14 (depends on 11)

The immunoassay solid support of claim 11, wherein said multiple epitope fusion antigen comprises the amino acid sequence depicted in SEQ ID NO:10, or an amino acid sequence with at least 98% sequence identity thereto which reacts specifically with anti-HCV antibodies present in a biological sample from an HCV-infected individual.

### Claim 15 (depends on 11)

The immuno assay solid support of claim 11, wherein said multiple epitope fusion antigen consists of the amino acid sequence depicted in SEQ ID NO:10.

### Claim 16 (depends on 1)

A method of detecting hepatitis C virus (HCV) infection in a biological sample, said method comprising:
(a) providing an immunoassay solid support according to claim 1;
(b) combining a biological sample with said solid support under conditions which allow HCV antibodies, when present in the biological sample, to bind to said polypeptide to form a first immune complex;
(c) adding to the solid support from step (b) under complex forming conditions a detectably labeled antibody, wherein said labeled antibody is reactive with said immune complex;
(d) detecting second immune complexes formed between the detectably labeled antibody and the first immune complex, if any, as an indication of HCV infection in the biological sample.

### Claim 17 (depends on 11)

A method of detecting hepatitis C virus (HCV) infection in a biological sample, said method comprising:
(a) providing an immunoassay solid support according to claim 11;
(b) combining a biological sample with said solid support under conditions which allow HCV antibodies, when present in the biological sample, to bind to said polypeptide and/or said multiple epitope fusion antigen to form a first immune complex;
(c) adding to the solid support from step (b) under complex forming conditions a detectably labeled antibody, wherein said labeled antibody is reactive with said immune complex;
(d) detecting second immune complexes formed between the detectably labeled antibody and the first immune complex, if any, as an indication of HCV infection in the biological sample.

### Claim 18 (depends on 1)

An immunodiagnostic test kit comprising the immunoassay solid support of claim 1, and instructions for conducting the immunodiagnostic test.

### Claim 19

An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:2, wherein the polypeptide comprises an NS3 conformational epitope.

### Claim 20 (depends on 19)

The isolated polypeptide of claim 19, wherein the polypeptide consists of the amino acid sequence of SEQ ID NO:2.

### Claim 21

An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:4, wherein the polypeptide comprises an NS3 conformational epitope.

### Claim 22 (depends on 21)

The isolated polypeptide of claim 21, wherein the polypeptide consists of the amino acid sequence of SEQ ID NO:4.

### Claim 23

An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:6, wherein the polypeptide comprises an NS3 conformational epitope.

### Claim 24 (depends on 23)

The isolated polypeptide of claim 23, wherein the polypeptide consists of the amino acid sequence of SEQ ID NO:6.

### Claim 25 (depends on 19)

A polynucleotide comprising a coding sequence for the polypeptide of claim 19.

### Claim 26 (depends on 21)

A polynucleotide comprising a coding sequence for the polypeptide of claim 21.

### Claim 27 (depends on 23)

A polynucleotide comprising a coding sequence for the polypeptide of claim 23.

### Claim 28 (depends on 25)

A recombinant vector comprising:
(a) a polynucleotide according to claim 25;
(b) and control elements operably linked to said polynucleotide whereby the coding sequence can be transcribed and translated in a host cell.

### Claim 29 (depends on 26)

A recombinant vector comprising:
(a) a polynucleotide according to claim 26;
(b) and control elements operably linked to said polynucleotide whereby the coding sequence can be transcribed and translated in a host cell.

### Claim 30 (depends on 27)

A recombinant vector comprising:
(a) a polynucleotide according to claim 27;
(b) and control elements operably linked to said polynucleotide whereby the coding sequence can be transcribed and translated in a host cell.

### Claim 31 (depends on 28)

A host cell transformed with the recombinant vector of claim 28.

### Claim 32 (depends on 29)

A host cell transformed with the recombinant vector of claim 29.

### Claim 33 (depends on 30)

A host cell transformed with the recombinant vector of claim 30.

### Claim 34 (depends on 31)

A method of producing a recombinant polypeptide comprising:
(a) providing a population of host cells according to claim 31; and
(b) culturing said population of cells under conditions whereby the polypeptide encoded by the coding sequence present in said recombinant vector is expressed.

### Claim 35 (depends on 32)

A method of producing a recombinant polypeptide comprising:
(a) providing a population of host cells according to claim 32; and
(b) culturing said population of cells under conditions whereby the polypeptide encoded by the coding sequence present in said recombinant vector is expressed.

### Claim 36 (depends on 33)

A method of producing a recombinant polypeptide comprising:
(a) providing a population of host cells according to claim 33; and
(b) culturing said population of cells under conditions whereby the polypeptide encoded by the coding sequence present in said recombinant vector is expressed.

### Claim 37 (depends on 19)

A method of producing an immunoassay solid support, comprising:
(a) providing a solid support; and
(b) binding to the solid support at least one polypeptide according to claim 19.

### Claim 38 (depends on 21)

A method of producing an immunoassay solid support, comprising:
(a) providing a solid support; and
(b) binding to the solid support at least one polypeptide according to claim 21.

### Claim 39 (depends on 23)

A method of producing an immunoassay solid support, comprising:
(a) providing a solid support; and
(b) binding to the solid support at least one polypeptide according to claim 23.

### Claim 40 (depends on 37)

The method of claim 37, further comprising binding to the solid support at a discrete position a multiple epitope fusion antigen.

### Claim 41 (depends on 38)

The method of claim 38, further comprising binding to the solid support at a discrete position a multiple epitope fusion antigen.

### Claim 42 (depends on 39)

The method of claim 39, further comprising binding to the solid support at a discrete position a multiple epitope fusion antigen.
